ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF

The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: FU, Jun, HUO, Yongting, LU, Lisheng, LI, Fan, ZHANG, Zhe, LU, Di, GONG, Chunxi
Format: Patent
Sprache:chi ; eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator FU, Jun
HUO, Yongting
LU, Lisheng
LI, Fan
ZHANG, Zhe
LU, Di
GONG, Chunxi
description The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD-1 to PD-L1 and PD-L2. Therefore, the antibody or antigen-binding fragment thereof, and its related nucleic acid, vector, cell, or pharmaceutical composition can be used to prepare a medicament for the treatment of PD-1 mediated diseases or conditions. La présente demande relève du domaine de la technologie biomédicale, et concerne en particulier un anticorps humanisé anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci et une utilisation associée. L'anticorps peut se lier de manière efficace et spécifique à PD-1, et peut bloquer de manière efficace la liaison de PD-1 à PD-L1 et PD-L2. Par conséquent, l'anticorps ou le fragment de liaison à l'antigène de celui-ci, et son acide nucléique, vecteur, cellule ou
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022258011A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022258011A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022258011A13</originalsourceid><addsrcrecordid>eNrjZIhw9Avx1A1w0TVU8Aj1dfTzjHJ1UQCJOfm7RCr4B4HZ7q5-uk6efi6efu4KbkGO7r6ufiEKIR6uQa7-bkAFQA0BAT6ezo4hnv5-MHEeBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhIf7m9kYGRkZGphYGjoaGhMnCoAgtIxyw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF</title><source>esp@cenet</source><creator>FU, Jun ; HUO, Yongting ; LU, Lisheng ; LI, Fan ; ZHANG, Zhe ; LU, Di ; GONG, Chunxi</creator><creatorcontrib>FU, Jun ; HUO, Yongting ; LU, Lisheng ; LI, Fan ; ZHANG, Zhe ; LU, Di ; GONG, Chunxi</creatorcontrib><description>The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD-1 to PD-L1 and PD-L2. Therefore, the antibody or antigen-binding fragment thereof, and its related nucleic acid, vector, cell, or pharmaceutical composition can be used to prepare a medicament for the treatment of PD-1 mediated diseases or conditions. La présente demande relève du domaine de la technologie biomédicale, et concerne en particulier un anticorps humanisé anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci et une utilisation associée. L'anticorps peut se lier de manière efficace et spécifique à PD-1, et peut bloquer de manière efficace la liaison de PD-1 à PD-L1 et PD-L2. Par conséquent, l'anticorps ou le fragment de liaison à l'antigène de celui-ci, et son acide nucléique, vecteur, cellule ou</description><language>chi ; eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20221215&amp;DB=EPODOC&amp;CC=WO&amp;NR=2022258011A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20221215&amp;DB=EPODOC&amp;CC=WO&amp;NR=2022258011A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FU, Jun</creatorcontrib><creatorcontrib>HUO, Yongting</creatorcontrib><creatorcontrib>LU, Lisheng</creatorcontrib><creatorcontrib>LI, Fan</creatorcontrib><creatorcontrib>ZHANG, Zhe</creatorcontrib><creatorcontrib>LU, Di</creatorcontrib><creatorcontrib>GONG, Chunxi</creatorcontrib><title>ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF</title><description>The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD-1 to PD-L1 and PD-L2. Therefore, the antibody or antigen-binding fragment thereof, and its related nucleic acid, vector, cell, or pharmaceutical composition can be used to prepare a medicament for the treatment of PD-1 mediated diseases or conditions. La présente demande relève du domaine de la technologie biomédicale, et concerne en particulier un anticorps humanisé anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci et une utilisation associée. L'anticorps peut se lier de manière efficace et spécifique à PD-1, et peut bloquer de manière efficace la liaison de PD-1 à PD-L1 et PD-L2. Par conséquent, l'anticorps ou le fragment de liaison à l'antigène de celui-ci, et son acide nucléique, vecteur, cellule ou</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIhw9Avx1A1w0TVU8Aj1dfTzjHJ1UQCJOfm7RCr4B4HZ7q5-uk6efi6efu4KbkGO7r6ufiEKIR6uQa7-bkAFQA0BAT6ezo4hnv5-MHEeBta0xJziVF4ozc2g7OYa4uyhm1qQH59aXJCYnJqXWhIf7m9kYGRkZGphYGjoaGhMnCoAgtIxyw</recordid><startdate>20221215</startdate><enddate>20221215</enddate><creator>FU, Jun</creator><creator>HUO, Yongting</creator><creator>LU, Lisheng</creator><creator>LI, Fan</creator><creator>ZHANG, Zhe</creator><creator>LU, Di</creator><creator>GONG, Chunxi</creator><scope>EVB</scope></search><sort><creationdate>20221215</creationdate><title>ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF</title><author>FU, Jun ; HUO, Yongting ; LU, Lisheng ; LI, Fan ; ZHANG, Zhe ; LU, Di ; GONG, Chunxi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022258011A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng ; fre</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>FU, Jun</creatorcontrib><creatorcontrib>HUO, Yongting</creatorcontrib><creatorcontrib>LU, Lisheng</creatorcontrib><creatorcontrib>LI, Fan</creatorcontrib><creatorcontrib>ZHANG, Zhe</creatorcontrib><creatorcontrib>LU, Di</creatorcontrib><creatorcontrib>GONG, Chunxi</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FU, Jun</au><au>HUO, Yongting</au><au>LU, Lisheng</au><au>LI, Fan</au><au>ZHANG, Zhe</au><au>LU, Di</au><au>GONG, Chunxi</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF</title><date>2022-12-15</date><risdate>2022</risdate><abstract>The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD-1 to PD-L1 and PD-L2. Therefore, the antibody or antigen-binding fragment thereof, and its related nucleic acid, vector, cell, or pharmaceutical composition can be used to prepare a medicament for the treatment of PD-1 mediated diseases or conditions. La présente demande relève du domaine de la technologie biomédicale, et concerne en particulier un anticorps humanisé anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci et une utilisation associée. L'anticorps peut se lier de manière efficace et spécifique à PD-1, et peut bloquer de manière efficace la liaison de PD-1 à PD-L1 et PD-L2. Par conséquent, l'anticorps ou le fragment de liaison à l'antigène de celui-ci, et son acide nucléique, vecteur, cellule ou</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng ; fre
recordid cdi_epo_espacenet_WO2022258011A1
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
title ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A42%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FU,%20Jun&rft.date=2022-12-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022258011A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true